BSH 2018 | Discontinuing treatment and predicting relapse in CML

Adam Mead

Chronic myeloid leukemia (CML) stem cells are thought to evade treatment through disruption in the environment within the bone marrow, creating a proinflammatory microenvironment in which there is excessive tumor necrosis factor signaling. In this talk, Adam Mead, PhD, MRCP, FRCPath, from Oxford University Hospitals NHS Foundation Trust, Oxford, UK, outlines research using single cell genomics and real-world data to predict patients’ risk of relapse after treatment has ceased. This could prevent treatment being administered beyond requirement, although Dr Mead points out two factors that could prevent the widespread utilization of single cell genomics. Dr Mead touches upon the DESTINY study (NCT01804985), which is investigating the de-escalation of imatinib, nilotinib and dasatinib in CML, and the promising rates of treatment-free remission. This video was recorded at the British Society of Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.

Share this video